China Medical University Signs Cooperation Agreement with Pharmaceutical Organizations to Cultivate Professionals in Industrial Pharmacy
The global pharmaceutical industry is undergoing a major transformation driven by the "Pharma 4.0" vision. To assist Taiwanese companies in transitioning toward continuous pharmaceutical manufacturing, the Center for Drug Evaluation (CDE)—with support from the Industrial Development Administration under the Ministry of Economic Affairs—led a delegation of domestic pharmaceutical firms to visit continuous manufacturing equipment suppliers and research institutions in North America. This initiative aims to introduce advanced, intelligent manufacturing technologies to Taiwan’s pharmaceutical sector.
The Pharmaceutical Technology Center plays a pivotal role in advancing pharmaceutical formulation and manufacturing technologies in Taiwan, having made significant contributions to the progress of the island’s pharmaceutical sector. As the global "Pharma 4.0" movement gains momentum, mastering advanced manufacturing to bolster technical capabilities has become essential; this visit marks the beginning of a new era for Taiwan as it moves toward advanced, intelligent pharmaceutical manufacturing.
During this visit to North America, the delegation met with continuous manufacturing equipment suppliers—including Vector, GEA, and Glatt—as well as Professor Muzzio and the Center for Structured Organic Particulate Systems (C-SOPS) at Rutgers University in New Jersey. C-SOPS was the world’s first institution to establish an R&D platform for pharmaceutical continuous manufacturing. It operates as a consortium involving several major international pharmaceutical companies and is supported by the U.S. National Science Foundation. The center has long been dedicated to the development of continuous manufacturing and has also been commissioned by the U.S. Food and Drug Administration (FDA) to help formulate regulations concerning continuous manufacturing.
Dr. Muzzio, Director of C-SOPS, expressed high expectations for Taiwan’s advancement of continuous manufacturing. He noted that the Center for Drug Evaluation (CDE) currently plays a role in Taiwan similar to the one C-SOPS once held in the United States when it spearheaded the adoption of continuous manufacturing processes, and he looks forward to establishing a deep, collaborative partnership with Taiwan.
Moving forward, the Pharmaceutical Technology Center will leverage its established strengths in process analytical technology to collaborate with domestic industry players on the development of continuous manufacturing equipment and production modules, thereby accelerating innovation and upgrading within Taiwan’s pharmaceutical sector and facilitating expansion into international markets.